Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -0.37% 268.00 1,105,546 16:35:14
Bid Price Offer Price High Price Low Price Open Price
268.00 272.00 270.50 262.50 270.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.64 -21.34 -8.37 679
Last Trade Time Trade Type Trade Size Trade Price Currency
17:17:29 O 2,500 268.00 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Investors    Avacta Takeover Rumours

Avacta (AVCT) Discussions and Chat

Avacta Forums and Chat

Date Time Title Posts
13/5/202117:48Avacta – Innovative and Disruptive Technologies for Global Health Markets26,732
13/5/202112:16Covid-19. Ten Minute Test. Gamechanger!!18,893
23/4/202116:22avct The Fall!!!76
14/4/202118:18CV And The Deep State164
20/3/202116:18Avacta. 434

Add a New Thread

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 269p.
Avacta Group Plc has a 4 week average price of 226.50p and a 12 week average price of 168p.
The 1 year high share price is 290p while the 1 year low share price is currently 90p.
There are currently 253,236,345 shares in issue and the average daily traded volume is 2,104,240 shares. The market capitalisation of Avacta Group Plc is £678,673,404.60.
mark0419: ess Ads, More Data, More Tools Register for FREE   Share PricesAvacta Share PriceAvacta Share Chat?Avacta Share Chat (AVCT)?AVCT SharePrice?AVCT ShareNews1?AVCT ShareChat230?AVCT ShareTrades814?AVCTLive RNS1AVCT Information  ?Buy AVCT Shares?Add AVCT to Watchlist?Add AVCT to Alert?Add AVCT to myTerminal Share Price Information for Avacta (AVCT)? Share Price is delayed by 15 minutesGet Live DataShare Price:270.50Bid:270.00Ask:271.00Change:8.50 (3.24%) Spread: 1.00 (0.37%)Open: 257.50High: 275.50Low: 262.50Yest. Close: 262.00?Last checked at 12:31:20Share Discussion for AvactaRegular Premium Filters Post Message123MR.SpacetomatoPrice: 271.00Strong BuyRE: On sale USA soonToday 12:30Well spotted Energyshares! I guess we are covering China as well!!showPrice: 272.00No OpinionThe Group "Has Developed" its LFT using AffimersToday 12:30Great to finally see the phrase 'Has Developed', rather than the usual 'Is Being Developed'!"The Group has developed a SARS-CoV-2 antigen lateral flow test using its Affimer® platform"All done and dusted!LivedataaccountPrice: 272.00No OpinionRE: .Today 12:28Jrdc, that crossed my mind.If avacta were only concentrating on European sales would they still need to do the dhsc submission?urbansea89Price: 271.50No OpinionRE: Resistance brokenToday 12:27Thanks, the time of the RNS with keep us on our toes.Hugely exciting times ahead. I think even our Sujood could be underestimating the share price upside this year.MR.SpacetomatoPrice: 272.00No OpinionRE: SujoodToday 12:27Crispysweed: "He should now be referred to as the Messiah"!Yes, he is the Messiah..we know it as we followed a few!WigglyPrice: 271.50No OpinionRE: On sale USA soon......................As a reminder, the following is a list of tests with FDA authorisation and note that AVCT beats all on sensitivity (at a high CT 31) and very likely beats all on spec when sample size is level/increased.If you think AVCT wont be on sale in the USA via licence you are wrong!- AVCT/100/99/AN/S/LOD TBCManufacturer Name/Sensitivity/Specificity/Specimen/TargetGene/LOD- Celltrion/94.4/100/NS/S/3.2 × 10^1 TCID50/mL- Qorvo/90/100/AN/N/125,000 genome equivalents/mL- Abbott/91.7/100 (symptomatic)/NS/N/22.5 TCID50/swab- Quidel/97/100/AN + NS/N/226 TCID50/mL-Becton/84 (symptomatic)/100(symptomatic)/NS/140 TCID50/mL-Princeton/93.9/99.3/NA/N/2.7 x 10^3 TCID50/mL (SARS-CoV-2)-Access/87.2/99.3/AN/N/800 TCID50/mL-OrthoClinical/80/100/NS/N/500-1500 TCID50/mL- LumiraDx/97.6/96.6/NS/N/32 TCID50/mL
pwhite73: Raj - "You must agree this GAD contract will only further pave the way for AVCT to monopolise the European and Far East markets.".."THAT therapeutic will be the holy grail and will make AVCT a world renown company." You all understand the technology because its in the RNS statements and on their website. What I've repeatedly tried to get over and what you don't understand is the competitive nature of the market AVCT is operating in. If AVCT have the best product on the market it does not mean they will sign a single contract. Other companies will defend their less effective products to the death. End licence users are already tied into contracts for these less effective products that may not expire until another year or so. Even if they preferred AVCT they cannot just switch overnight. They need to trial the product for 1 - 2 years to satisfy insurance companies that cover for any failure, illnesses or deaths. If the products are backed by a government then that's a different ball game because the government takes responsibility for any mishaps. When/if AVCT ever releases its next LFT update I expect all the above to be included.
lukead: · 30 Apr Seems odd #AVCT don't want to say anything about DHSC selecting a test and the timescales around that process. I appreciate ODX need to explain what dependencies their manufacturing capacity assignment will rely on, but even so... @MylesMcNulty 30 Apr I‘s suggest it’s because DHSC and @avacta are deep in negotiations over margin. The four manufacturers will likely all get a similar cut; #AVCT will likely get the lion’s share of the margin, as test developer / owner. I think Mologic will also get a minor profit share. All IMO! @seidy14 30 Apr Hey Myles, what do you think of Mologic’s validation results that came back from Germany? 100% specificity! And circa 97% sensitivity. Is the better specificity a worry for #AVCT? @seidy14 @MylesMcNulty 2 May Morning, no it’s not a worry for me. If #AVCT’s LFT had yielded two false positives, I would be. 127/128 however - I’m treating the 1 as an unfortunate outlier. @seidy14 · 2 May Do you think it is possible the DHSC will perhaps choose 2 sovereign tests? #AVCT & Mologic seeing as Mologic’s results were also very good? @MylesMcNulty · 2 May Certainly possible, of course. @seidy14 Hi Myles, can you share your thoughts on the #AVCT vs Mologic debate as to where you feel both tests stand at the minute & which 1 of the tests is likely to be selected as the Sovereign test? Thanks @MylesMcNulty Replying to @seidy14 Hi UAI, the @mologic test missed multiple positive cases at a Ct of <25. The @avacta test missed zero positive cases at a Ct of <27. I am largely ignoring the noise around #AVCT and #ODX on Twitter, as I really cannot see how there can even be a debate. 9:14 pm · 5 May 2021·Twitter
tickboo: The market/share price disagrees as since the announcement on 23 Nov we are some 30% above the share price then. Deary me. You can but try.
pwhite73: You seem to forget the reason why AVCT share price raced ahead was because it was in the process of inventing a new type of LFT namely a saliva swab. This was far more comfortable, preferable and easier to use than nasophyrangeal swaps that tickled your brain. The LFT saliva swab failed. AVCT switched tack in Nov 2020 and came up with the anterior nasal swab. AVCT is late to the game. Now whether the last shall be first we shall soon see.
pwhite73: zydecoco - "How much AVCT do you hold PWhite73?" I am not a holder in AVCT yet but believe they will be a buy when all the Covid froth has been removed. AVCT has good cancer products in the pipeline and its Affirmer is world class. Before jumping on the Covid bandwagon (RNS 08/04/2020) the company share price was just 15p and the market cap £26 million. Today the share price is 262p and the market cap is £673 million. To December 2020 the company had sales of just £3.2 million (I kid you not) and losses of £21 million. If you take NCYT to December 2020 they had sales of £277 million, profits of £187 million and today have a market cap of £323 million. AVCT is valued at more than twice the market cap of NCYT and technically has zero sales and operates at a loss. It is plain to see the company is seriously overvalued and it is for people like you I am here. As the pandemic draws to a close in the UK and Europe due to vaccinations NCYT share price has collapsed from 1200p to 467p today. AVCT share price will be corrected and shortly I just don't want you to be holding when it happens. Speak Later
pwhite73: JonC - "Why has PW become the focus of attention." Quite simple. Unpalatable truths. If I came here just to spout that AVCT was going bust next week or the share price will crash tomorrow shareholders can handle that. To give reasons why AVCT are not selling any Covid test kits causes a whole load of problems. When you see posters using the F and C words to get across a point it indicates they are not genuine shareholders they are gamblers. "F with my money and I'll F you up you C". That's their mentality. Proper long term shareholders have done their research/homework and have the knowledge to argue their case and will even admit if they've overlooked something. These are the people I'm addressing here.
pwhite73: Raj - AVCT only had one LFT test on the market which was its saliva swab test. They entered into a contract with ABDX to manufacture the test (RNS 02/09/2020). The DHSC terminated the contract with ABDX effective from 14/02/2021 (RNS 27/04/2021) it is unclear exactly what they sold to the DHSC. So what have AVCT got left?. On 23/11/2020 AVCT announced it was launching an anterior nasal LFT. The DHSC has published the latest list of LFT that have passed phase 3a test and are suitable for mass commercial use. I've posted the link already here it is again. AVCT are not on the list. On 20/04/2021 it claims to have passed the final clinical validation. To be on the list a company doesn't carry out its own clinical validation as AVCT did the clinical validation is carried out by PHE Porton Down and Oxford University. "Since its establishment in August 2020, the joint PHE Porton Down and University of Oxford SARS-CoV-2 lateral flow antigen test validation cell has evaluated over 120 lateral flow devices that have been referred by the Department of Health and Social Care (DHSC)" You will note Innova are on the list. You will also note neither OMG or Global Access Diagnostics are on the list. This is because they have been awarded contracts to mass produce other manufacturers LFT that the DHSC has approved not their own!!!. Of course there is nothing to stop them using spare capacity to manufacture their own LFT or anybody else's including AVCT. As Blackculture said AVCT also produce a highly effective Affimer so investors can easily get muddled up between what is an LFT contract and an Affirmer contract and AVCT do this deliberately. Conclusion DHSC approved LFTs go through the same process as drugs. Phase I II and III at each stage the regulatory body decides if the LFT can move onto the next stage and then finally onto mass production for commercial use. The AVCT LFT is not part of this process. AVCT has no LFT contracts at the moment. Whether it signs any when it gets its CE mark from Mologic is yet to be seen.
indyanna: We don't need FUMs MED3000 thanks, the AVCT share price gives us a hard on ?
mark0419: : Market Cap going forwardToday 12:57Crazy undervalued right now, feel that the market is only expecting 5m a month. But as said before from trusted sources will be getting at 2m+ a day which ties in perfectly with what the DPS said back in Feb with a spend of up to £10b a YEAR.Broker note stated would be £7 a test and would get 30% margin.. So lets assume the broker note is correct.5m a month is £420m rev / £126m profit a year.. (Pretty much supports our current share price in itself).Now lets bump that up to the 2m a day additional capacity, so:65m a month is £5,46billion rev a year / £1,638b profit a year.Now calculate that vs our market cap, looking at £21.50 share price ish just based on the LFD alone, excluding everything else.Then throw in a PE value of 2. Why not even throw in 10% for royalties by white labelling the test abroad..The figures start getting insane and many many multiples of where we are at today.Alastair made no mistake when he said:"Avacta will become a multi-billion-dollar life sciences company competing globally with the likes of Roche-Genentech, Thermo-Fisher and Abbott". They are valued at around 200billion market cap each.
Avacta share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210513 16:52:00